MYRAMISTIN® has a profound antibacterial effect, even in hospital strains with antibiotic resistance.
MYRAMISTIN® is the most effective for fighting gram-positive bacteria (Staphylococcus spp., Streptococcus spp., Streptococcus pneumoniae, etc.), Gram negative (Pseudomonas aeruginosa, Escherichia coli, Klebsiella spp., Etc.), Aerobic bacteria and anaerobics in the form of monocultures and associations of microbes, including hospital strains with multiresistance to antibiotics.
MYRAMISTIN® exerts an anti-mycotic effect on Aspergillus and Penicillium, saccharomyces (Rhodotorula rubra, Torulopsis gabrata, etc.) and saccharomyces (Candida albicans, Candida tropicalis, Candidakrusei, Pityrosporum orbiculare (Malassezia furfur), dermatophytes (Trichophyton) rubrum, Trichophyton mentagrophytes , Trichophytonverrucosum, Trichophyton schoenleini, Trichophyton violacent, Epidermophyton Kaufman-Wolf, Epidermophyton floccosum, Microsporum gypseum, Microsporum canis, etc.) and any other pathogenic fungus, in the form of monocultures and microbial association, including one of the fungal microflora characterized by its resistance to chemotherapeutic drugs.
MYRAMISTIN® exerts an antiviral action, is active compared to complex viruses (herpes, human immunodeficiency virus, etc.).
MYRAMISTIN® suppresses microbes that cause sexually transmitted infections (Chlamydia spp., Treponema spp., Trichomonas vaginalis, Neisseria gonorrhoeae, etc.).
MYRAMISTIN® effectively prevents the contamination of wounds and burns. Stimulates the regeneration processes. It stimulates the protective responses at the injection sites by stimulating the function of the phagocytes to overwhelm and digest and enhance the activity of the monocytic system of macrophages. It exerts a vigorous hyperosmolar action that allows a substantial reduction of the peripheral wound and inflammation, absorbs the purulent exudate, allowing the formation of dry crusts. It does not destroy the granulation and the vital cells of the skin; does not oppress the epithelialization of the border.
It does not present local irritation and allergic properties.
Following the local administration, MYRAMISTIN® is not absorbed through the skin and mucous membranes.
Surgery and traumatic surgery: prevention of suppuration and treatment of infected wounds and suppurative inflammatory processes in the locomotor system.
Obstetrics and gynecology: prevention and treatment of postnatal suppurative lesions, perineum and vaginal wounds, post-natal infections, inflammatory diseases (vulvovaginitis and endometritis).
Kombustology: treatment for minor and severe burns of the second and third degree, preparation of burns for dermatoplasty.
Dermatology and venereology: prevention and treatment of pyoderma and dermatomyocytosis, candidiasis of skin and mucous membranes, unique mycosis.
Individual preventive treatment of sexually transmitted infections (syphilis, gonorrhea, chlamydia, trichomoniasis, genital herpes, genital candidiasis, etc.).
Urology: complex treatment for acute and chronic urethritis and general and specific urethrostostatitis (chlamydosis, trichomoniasis, gonorrhea) and non-specific types.
Stomatology: prevention and treatment of infectious and inflammatory diseases of the oral cavity: stomatitis, gingivitis, paracementitis and pericatitis. Hygienic treatment of separable prostheses.
Otorhinolaryngology: complex treatment of acute and chronic otitis, antritis, tonsillitis, laryngitis and pharyngitis.
Pediatric use: MYRAMISTIN® is used in patients aged 3 to 14 for the complex treatment of acute pharyngitis and / or chronic tonsillitis relapse.
Idiosyncrasy for the drug.